INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE);UNIVERSITÉ PARIS DIDEROT - PARIS 7;COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA);UNIVERSITÉ PARIS-SUD
发明人:
MAGNON, Claire,ROMEO, Paul-Henri
申请号：
EPEP2019/059698
公开号：
WO2019/197683A1
申请日:
2019.04.15
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
The invention relates to methods for predicting the outcome of a patient suffering from prostate cancer or breast cancer and methods for the treatment of prostate cancer or breast cancer. The inventors show that Doublecortin-expressing (DCX+) neural precursors from the central nervous system (CNS) enter the bloodstream, infiltrate prostate tumours and metastasis and differentiate into neo-neurons that contribute to tumour development. In human primary prostate tumours and transgenic mouse cancer tissues, the density of DCX+ neural progenitors is strongly associated with tumour aggressiveness, invasion and recurrence. In transgenic cancer mice, oscillations of DCX+ neural stem cells in the subventricular zone (SVZ), a neurogenic area of the CNS, were associated with egress of DCX+ cells from the SVZ to the bloodstream. These cells then reach the tumour where they initiate neurogenesis. Selective genetic depletion of DCX+ cells in mice inhibits the early phases of prostate cancer development, whereas ortho topic transplantation of DCX+ cells purified from prostate tumour or brain tissues promotes tumour growth and cancer cell dissemination. These results unveil a unique crosstalk between the CNS and the tumour that drives a process of neurogenesis necessary for prostate cancer development, and indicate a novel neural element of the tumour microenvironment as a potential target for cancer treatment. Thus, the invention relates to a method for predicting the outcome of a patient suffering from prostate cancer and compound targeting DCX+ neural progenitor cells for use in the treatment of prostate cancer.L'invention concerne des procédés de prédiction de l'évolution d'un patient souffrant d'un cancer de la prostate ou d'un cancer du sein et des procédés pour le traitement du cancer de la prostate ou du cancer du sein. Les inventeurs ont mis en évidence que des précurseurs neuronaux exprimant la doublecortine (DCX+) du système nerveux central (SNC) entrent dans la circula
